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Abstract Chronic activation of Gq coupled receptors, or
overexpression of GKq, in cardiomyocytes results in hypertrophy,
enhanced expression of fetal genes, decreased basal and L-
adrenergic receptor (LAR) stimulated adenylyl cyclase (AC)
activities, and depressed cardiac contractility in vivo. Among
several abnormalities of the LAR-Gs-AC pathway that occur in
GKq overexpressing transgenic mice, we have investigated
whether the observed V45% decrease in type V AC expression
and function compared to non-transgenic (NTG) is the basis of
the above phenotype. Transgenic mice were generated that
overexpressed byV50% the rat type V AC in the heart using the
K-myosin heavy chain promoter. These mice were mated with the
GKq transgenics resulting in animals (ACV/GKq) that had
restored levels of forskolin stimulated AC activities in cardiac
membranes. In addition, basal cardiac AC activities were
normalized in the ACV/GKq mice (NTG = 23 þ 4.4,
GKq = 14 þ 3.6, ACV/GKq = 29 þ 5.3 pmol/min/mg) as were max-
imal isoproterenol stimulated activities (59 þ 8.9, 34 þ 4.6,
52 þ 6.7 pmol/min/mg respectively). Cardiac contractility was
also improved by ACV replacement, with increased fractional
shortening (51 þ 2%, 36 þ 6%, 46 þ 3% respectively). In contrast,
hypertrophy and expression of hypertrophy associated fetal
genes were not affected. Thus the observed decrease in type V
AC that accompanies the development of the cardiac phenotype
in the GKq model is the dominant mechanism of dysfunctional
LAR signalling and contractility. In contrast, the decrease in type
V AC or LAR signalling to cAMP is not the basis of the
hypertrophic response.
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1. Introduction
Chronic activation of cardiomyocyte surface receptors such
as those for epinephrine, endothelin-1, prostaglandin F2K, and
angiotensin II causes a series of events that culminate in my-
ocyte hypertrophy and contractile dysfunction (reviewed in
[1]). A common feature of these receptors is that they couple
to the Gq class of heterotrimeric G proteins, suggesting that
activation of Gq signalling by these agents represents a com-
mon point of convergence which is necessary to evoke the
phenotype. Recently we have further explored this notion at
the biochemical and physiological level by overexpressing the
K subunit of Gq in the hearts of transgenic mice [2]. The mice
develop cardiac hypertrophy, depressed ventricular contractil-
ity at baseline and in response to L-adrenergic receptor (LAR)
agonists, diminished basal and agonist stimulated adenylyl
cyclase activity, and activation of a fetal cardiac gene program
with increases in atrial natriuretic factor (ANF) and L-myosin
mRNA [2].
Recent studies have delineated several potential mecha-
nisms of LAR dysfunction in these mice which are associated
with ventricular dysfunction and LAR unresponsiveness in
vivo [2,3]. These include an uncoupling of the LAR from
Gs, an increase in GKi, and a decrease in expression and/or
function of adenylyl cyclase. In contrast to other mouse mod-
els of hypertrophy [4], the GKq mouse does not exhibit
changes in expression of LAR or the LAR kinase [3]. The
decrease in adenylyl cyclase expression and catalytic activity,
which amounts to V45% loss of type V adenylyl cyclase, is
particularly intriguing since adenylyl cyclase expression has
been reported to constrain LAR signalling in rat neonatal
myocytes [5]. Furthermore, adenylyl cyclase gene expression
or function is depressed in several other animal models of
heart failure [6^8]. Because the cardiac hypertrophy and sys-
tolic dysfunction in the GKq mouse are associated with im-
paired LAR signalling which may be multifactorial (at the
level of the receptor, G protein and adenylyl cyclase) we
have sought to identify cause-and-e¡ect relationships at each
level and to identify the rami¢cations of correcting each bio-
chemical lesion. In so doing, an assignment of a molecular
basis for the various facets of the GKq phenotype can be
made. In this report, we have overexpressed type V adenylyl
cyclase in transgenic mice to a level that would be expected to
achieve replacement when mated to GKq mice. These trans-
genic mice displayed enhanced catalytic activity consistent
with functionally overexpressed adenylyl cyclase and dis-
played no deleterious consequences from such overexpression.
The type V adenylyl cyclase (ACV) transgenics were then
mated to the GKq overexpressers, and the biochemical and
physiologic consequences were investigated.
2. Materials and methods
2.1. Transgenic mice
Transgenic mice of the FVB/N background which overexpress GKq
V5 fold over background (GKq40) have been previously described [2]
and are hereafter referred to as GKq mice. To create the ACV over-
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expressers the rat cDNA for type V adenylyl cyclase (obtained from
R. Premont, Duke University) was digested with XhoI releasing a
fragment consisting of 434 bp of 5P untranslated sequence, followed
by the 3787 bp of the coding region sequence and 231 bp of the 3P
untranslated sequence. This was ligated into the SalI site of the full
length K-myosin heavy chain (KMHC) promoter construct. The integ-
rity of the construct was con¢rmed by sequencing. DNA for micro-
injection was liberated from the KMHC-ACV plasmid by BamHI
digestion and microinjection into male pronuclei of FVB/N embryos
was carried out by standard procedures.
2.2. Transgene identi¢cation
Pups were screened via Southern analysis using EcoRI digested
genomic DNA extracted from tail clips. The probe used to detect
presence of the transgene was a 32P labeled (random priming method)
4 kb EcoRI fragment of the KMHC/ACV plasmid consisting of V1.9
kb of the KMHC promoter and V2.1 kb of the type V cDNA. A
heterozygous line (designated 14.3) which expresses ACV V50% over
background non-transgenic levels was chosen for mating to hetero-
zygous GKq overexpressing mice. The presence of the two transgenes
was determined by Southern blot using the above probe and a pre-
viously described GKq probe [2]. First and second generation double
(denoted ACV/GKq) and single transgenic and non-transgenic litter-
mates, at ages 12^16 weeks, were used for all studies.
2.3. Adenylyl cyclase activities
Ventricles were homogenized with a Polytron for 10 s in cold 5 mM
Tris (pH 7.40), 2 mM EGTA bu¡er containing the protease inhibitors
(5 Wg/ml) leupeptin, PMSF, soybean trypsin inhibitor, benzamidine
and aprotinin. Homogenates were centrifuged at 500Ug for 10 min
at 4‡ and the pellet discarded. The supernatant was centrifuged at
40 000Ug for 10 min and the pellet resuspended in a bu¡er that
provided for a ¢nal concentration in the adenylyl cyclase reaction
of 2 mM Tris, 4.8 mM MgCl2, 0.8 mM EGTA, pH 7.40, with the
aforementioned protease inhibitors. Adenylyl cyclase activities were
measured essentially as previously described [3]. The reaction (50 Wl
¢nal volume) consisted of membranes (V10 Wg) and 2.8 mM phos-
phoenolpyruvate, 0.06 mM GTP, 0.12 mM ATP, 0.1 mM cAMP, 4 U/
ml myokinase, 10 U/ml pyruvate kinase, 0.1 mM ascorbic acid, and
3U106 dpm [K-32P]ATP. Reactions were carried out for 10 min at
37‡C and contained various concentrations of isoproterenol or 100 WM
forskolin. Reactions were stopped by dilution with 1.0 ml of a 4‡
solution containing excess ATP and cAMP, and 25 000 dpm/ml
[3H]cAMP used to determine column recovery. [32P]cAMP was sepa-
rated by chromatography over alumina columns.
2.4. Radioligand binding
For determination of total LAR density, reactions consisted of
membranes (V50 Wg) and 400 pM 125I-CYP in the absence and pres-
ence of 1.0 WM alprenolol, used to de¢ne non-speci¢c binding [9].
Binding reactions were carried out for 2 h at 25‡C and terminated
by dilution and rapid ¢ltration over GF/C (Whatman) ¢lters. Speci¢c
binding, de¢ned as total minus non-speci¢c, was normalized to pro-
tein, and is expressed as fmol/mg.
2.5. Northern blots
Total RNA was extracted from cardiac tissue using Tri-Reagent
(Molecular Research Center Inc., Cincinnati, OH) and the manufac-
turer’s protocol. Cardiac gene expression was compared in non-trans-
genic and transgenic animals using RNA dot blotting and gene spe-
ci¢c antisense oligonucleotides [10], as previously described [2].
Brie£y, 2 Wg of RNA was denatured and blotted to Hybond N
membranes. After blotting, membranes were prehybridized for 1 h
at 55‡C in a solution containing 5USSC, 0.5% SDS, 1UDenhardt’s,
and 90 Wg/ml salmon sperm DNA. Samples were then hybridized with
32P labeled DNA probes for 5 h at 55‡C and washed. Gene expression
was quantitated using a PhosphorImager and ImageQuant Software.
Signal intensities for each dot were normalized to GAPDH to account
for small di¡erences in loading.
2.6. Echocardiography
Echocardiography was performed in mice sedated with intra-
peritoneal Avertin (1.0 ml/g of a 2.5% solution) as described [2]. Frac-
tional shortening (FS) was calculated from the end-systolic and end-
diastolic dimensions (ESD and EDD, respectively) by the formula:
FS = (EDD3ESD)/EDD.
2.7. Histopathology
Following dissection, whole hearts from 12 week old mice were
¢xed in 10% neutral bu¡ered formalin for 24 h and dehydrated in
70% ethanol. Hearts were embedded in para⁄n and sectioned in the
long axis. Sections 4 Wm in thickness were stained with hematoxylin
and eosin or Masson’s trichrome stain and examined microscopically.
2.8. Statistical analysis
Results from studies were compared by paired or unpaired t-tests as
appropriate. P values 6 0.05 were considered signi¢cant. Curve ¢tting
of dose-response data was carried out by an iterative least squares
technique using software from GraphPad (San Diego, CA). Data are
presented as mean þ S.E.M. of the indicated number of independent
experiments, each performed with a di¡erent mouse.
3. Results and discussion
We have hypothesized that the reduction in adenylyl cyclase
expression and function in the GKq mice could su⁄ciently
alter the stoichiometric equilibrium between receptor, Gs,
and adenylyl cyclase such that LAR signalling is impaired.
Thus, we bred the GKq mice with a relatively low overexpress-
er of ACV in order to achieve replacement levels of the cy-
clase. The ACV/GKq mice maintained an V5 fold increased
expression of GKq in the heart (data not shown). Forskolin
stimulated adenylyl cyclase activities were determined in car-
diac membrane to assess function of the type V adenylyl cy-
clase transgene (Fig. 1). These activities were V50% lower in
the GKq mice compared to non-transgenic littermates
(273 þ 68 vs. 533 þ 91 pmol/min/mg, n = 4, P6 0.005). The
ACV/GKq crosses had forskolin stimulated activities
(819 þ 160 pmol/min/mg) that were clearly increased over the
GKq mice (P6 0.02) and were indeed somewhat higher than
those of non-transgenic littermates (P = 0.04, Fig. 1). As pre-
viously reported GKq mice do not display a downregulation of
cardiac LAR expression [2]. The type V adenylyl cyclase trans-
genics and the ACV/GKq crosses also had LAR expression
levels that were no di¡erent from those of non-transgenic
littermates (25 þ 5.8 and 28 þ 4.9, vs. 28 þ 3.2 fmol/mg, n = 3^
5, P = NS). Basal and isoproterenol-stimulated activities are
Fig. 1. Functional properties of the ACV transgene. Cardiac mem-
branes were prepared from non-transgenic (NTG), heterozygous
GKq overexpressing transgenic mice, heterozygous ACV overexpress-
ing transgenic mice, and dual heterozygous ACV/GKq mice. Maxi-
mal catalytic adenylyl cyclase activity was determined by incubation
with 100 WM forskolin. Data are normalized to the NTG response.
GKq hearts have V50% decreases in basal and forskolin stimulated
adenylyl cyclase activities. Transgenic expression of ACV resulted in
an enhanced stimulation which is not counterregulated in the ACV/
GKq mice. Results are from ¢ve independent experiments.
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shown in Fig. 2. Basal adenylyl cyclase activities were reduced
in the GKq transgenic mice compared to non-transgenic litter-
mates (14.5 þ 3.6 vs. 23.2 þ 4.4 pmol/min/mg). Basal activities
of the ACV/GKq crosses were 29.5 þ 5.3 pmol/min/mg, which
were not statistically di¡erent from non-transgenic basal ac-
tivities. Maximal isoproterenol stimulated activities of the GKq
mice were lower (34.4 þ 4.6 vs. 59.5 þ 8.9 pmol/min/mg) and
the EC50 values higher (270 þ 20 nM vs. 149 þ 7 nM,
P6 0.005) as compared to non-transgenics (NTG). The
ACV/GKq crosses revealed a maximal response of 52.2 þ 6.7
pmol/min/mg, which was not di¡erent from that of non-trans-
genic littermates. The EC50 for this response was 209 þ 64 nM
(P = 0.19 compared to NTG). So from these data it appears
that LAR sensitivity and maximal responsiveness were fully
restored in GKq mice by replacement of type V adenylyl cy-
clase. Since an increase in Gi is another potential mechanism
for the GKq phenotype, and it is conceivable that increased
adenylyl cyclase could regulate Gi, we assessed GKi3 levels in
the hearts by Western analysis. The levels of GiK3 were iden-
tical in extracts from GKq and ACV/GKq mice (data not
shown).
Ventricular function was assessed by echocardiography
(Fig. 3). Consistent with our previous study [2], both end-
systolic and end-diastolic dimensions were increased in GKq
mice and left ventricular fractional shortening was decreased
(36 þ 6% as compared to 51 þ 2% for non-transgenic litter-
mates, P6 0.05). In the ACV/GKq crosses, end-systolic and
end-diastolic dimensions were improved and the fractional
shortening was increased to 46 þ 3%, which is not statistically
di¡erent from that found with non-transgenic littermates
(P = 0.27). As indicated, the GKq mice have lower heart rates
compared to non-transgenic littermates (286 þ 28 vs. 429 þ 25
bpm). The ACV/GKq crosses had intermediate heart rates of
388 þ 13 bpm which were not di¡erent from those of NTG
(P = 0.30).
In the GKq model of hypertrophy, we have also extensively
examined the cardiac expression of several fetal genes [2]. Of
the large assay initially assessed, levels of ANF and L-myosin
transcripts were substantially increased in the GKq mice com-
pared to non-transgenic littermates, and we have found these
to be sensitive indicators of improvements in hypertrophy [3].
The results of such RNA dot blot studies are shown in Fig. 4.
The GKq mice displayed 13.0 and 2.9 fold increases in expres-
sion of ANF and LMHC respectively. Co-expression of type
V adenylyl cyclase, which normalized LAR signalling and im-
proved cardiac function, does not appear to have a signi¢cant
e¡ect on ANF and LMHC gene expression (11.0 fold and 3.0
fold increased, respectively). Thus, based on these molecular
markers, hypertrophy persisted despite improved function.
Heart to body weight ratios con¢rmed these ¢ndings. The
GKq mice had enlarged hearts with ratios (mg/g) of
11.3 þ 1.0 compared to 8.2 þ 1.0 for NTG (P = 0.03). ACV/
GKq mice showed no decrement in this ratio (11.1 þ 1.7). His-
topathologic studies of GKq mice showed hypertrophic myo-
Fig. 2. LAR stimulated adenylyl cyclase activities are restored in
Gaq mice by transgenic replacement of ACV. Cardiac membranes
were prepared and activities determined in response to the indicated
concentrations of the L-agonist isoproterenol. Both basal and maxi-
mal isoproterenol stimulated activities were depressed in the GKq
mice compared to NTG. The EC50 for isoproterenol was also in-
creased (see text for results). The response from ACV/GKq cardiac
membranes was indistinguishable from NTG. Results are from ¢ve
independent experiments. *Overall response di¡erent from NTG,
P6 0.01.
Fig. 3. Ventricular function is improved in ACV/GKq mice. Echocar-
diograms were performed on the indicated transgenic mice. The GKq
phenotype is depressed fractional shortening and decreased heart
rate compared to NTG mice. When ACV is coexpressed (ACV/GKq
mice) fractional shortening and heart rates are increased and not
statistically di¡erent from those of NTG mice. Results are from 5^6
mice in each group. *P6 0.01.
Fig. 4. Genetic markers of hypertrophy are not altered by ACV re-
storation in GKq mice. RNA was extracted from the hearts of the
indicated mice and expression of transcripts for ANF and L-myosin
heavy chain (L-MHC) determined. Results are means from four
mice per line, normalized to the group mean expression of
GAPDH.
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cytes without in£ammation or a consistent degree of signi¢-
cant ¢brosis; ACV/GKq mice showed no improvement in the
hypertrophy with clear areas of ¢brosis (Fig. 5).
In the current studies we have shown that a signi¢cant
component of the signalling defect of LAR stimulation of
adenylyl cyclase in the GKq overexpressing model of hyper-
trophy and ventricular dysfunction is a decrease in the expres-
sion/function of cardiac type V adenylyl cyclase. Under the
conditions of GKq overexpression, which evokes a series of
pathologic sequelae that includes LAR dysfunction, we have
found several other potential mechanisms which may impair
LAR function. LAR physical coupling to GKs, as determined
in agonist competition studies in the absence of guanine nu-
cleotide, is decreased in cardiac membranes from GKq over-
expression. In addition, GKi2 and GKi3 levels are increased.
While any of these two, or the decrease in adenylyl cyclase,
could theoretically result in LAR dysfunction, explicit testing
to delineate the predominant mechanism is necessary. Given
that the stoichiometry of LAR to Gs to adenylyl cyclase in rat
myocytes has been reported [5] to be 1:200:3, a decrease in
the latter component, as is seen in the GKq overexpressing
mouse, has the potential to limit LAR signalling. We have
recently reported the results of overexpressing the L2AR in
the hearts of GKq mice [3]. A V30 fold overexpression failed
to improve isoproterenol stimulated adenylyl cyclase activ-
ities. With V140 fold overexpression partial restoration of
adenylyl cyclase responsiveness was observed. These data sug-
gested that alterations of a ‘downstream’ element of the signal
transduction cascade has a signi¢cant e¡ect on LAR signal-
ling. In the current report we show that a relatively small
increase in type V adenylyl cyclase, which essentially restores
catalytic function of the enzyme to normal (non-transgenic)
levels, results in full rescue of LAR stimulation of adenylyl
cyclase. Taken together, then, the evidence indicates that de-
creases in type V adenylyl cyclase have a major impact on
LAR signalling in this physiologically relevant mouse model.
Such modulation appears to have a direct impact on ventric-
ular function as well. Rescue of LAR signalling to adenylyl
cyclase was accompanied by signi¢cant improvement of ven-
tricular function when type V adenylyl cyclase levels were
restored. However, such improvement was not accompanied
by changes in hypertrophy. Thus the stimulus for develop-
ment of hypertrophy in the GKq mouse appears to be inde-
pendent of the decrease in LAR/cAMP signalling. Interest-
ingly, a prolonged decrease in sympathetic stimulation to
the heart may actually serve a protective e¡ect against wor-
sening failure [11]. Thus any gene therapy resulting in en-
hanced cardiac LAR function may be best suited for the acute,
rather than chronic, setting.
Our experimental design di¡ers markedly from that of Roth
et al. [12] who have reported the e¡ects of V20 fold over-
expression of type VI adenylyl cyclase in the heart. Type V
and VI isoforms di¡er in a number of key aspects [13^15].
Furthermore, based on studies in chick heart, type VI adenyl-
yl cyclase is thought to be minimally, if at all, expressed in the
cardiomyocyte [16]. Thus the aforementioned studies utilized
overexpression of a non-native cyclase to high levels. This
then likely represents ‘forced’ improvement without identi¢ca-
tion of a biochemical lesion per se. On the other hand, we
have expressed the dominant adenylyl cyclase isoform of the
Fig. 5. Cardiac histology. Shown are 4 Wm sections of left ventricles stained with Masson’s trichrome of NTG, ACV, GKq and ACV/GKq mice.
Magni¢cation is 100U.
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cardiomyocyte to a level that when these transgenic mice are
crossed with GKq mice, a restoration of this isoform to non-
transgenic levels is attained. In this way the mechanism of
LAR dysfunction in the GKq mouse could be directly explored.
In conclusion, there are several potential mechanisms that
cause a decrease in LAR signalling and depressed ventricular
function in GKq overexpressing transgenic mice. One of these,
a decrease in type V adenylyl cyclase, has been explicitly
tested by creating dual transgenic mice overexpressing the
cyclase and GKq. Our ¢ndings indicate that the decrease in
expression of type V adenylyl cyclase appears to be the major
basis for this defective LAR signalling, since restoration of
expression via transgenesis normalizes LAR signalling and
ventricular function.
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